^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DRD1 antagonist

    Related drugs:
    Associations

    News

    Trials
    7d
    SOLARIS: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (clinicaltrials.gov)
    P3, N=675, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Trial completion date: Oct 2025 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    olanzapine
    10d
    Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years (clinicaltrials.gov)
    P2, N=40, Completed, Emalex Biosciences Inc. | Unknown status --> Completed
    Trial completion
    10d
    The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine (clinicaltrials.gov)
    P4, N=13, Terminated, Sumitomo Pharma (Suzhou) Co., Ltd. | N=162 --> 13 | Active, not recruiting --> Terminated; Company's business decision
    Enrollment change • Trial termination
    |
    olanzapine
    13d
    A dopamine D1-like receptor-specific agonist improves the survival of septic mice. (PubMed, iScience)
    The D1-like receptor antagonist SCH-23390 abolished the anti-inflammatory effects of SKF. These data suggest that D1-like receptor-mediated signals in the brain prevent CLP-induced inflammation in both the brain and the periphery.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    17d
    HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial (clinicaltrials.gov)
    P3, N=72, Recruiting, Tan Tock Seng Hospital | Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    olanzapine
    21d
    Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder. (clinicaltrials.gov)
    P1, N=95, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    24d
    DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC. (PubMed, Mol Oncol)
    Interestingly, we also found that DRD1 regulates the expression of PD-L1 in lung cancer cells. Taken together, these results suggest that DRD1 methylation may constitute a biomarker of poor prognosis in NSCLC patients while other components of this pathway could be targeted to improve response to EGFR- and PD-L1-targeted therapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • MAPK1 (Mitogen-activated protein kinase 1) • DRD1 (Dopamine Receptor D1)
    |
    PD-L1 expression • EGFR expression
    26d
    Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial (clinicaltrials.gov)
    P3, N=87, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    27d
    An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (clinicaltrials.gov)
    P1, N=116, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    1m
    Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI) (clinicaltrials.gov)
    P3, N=146, Not yet recruiting, Foundation for Advancing Veterans' Health Research
    New P3 trial
    1m
    Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia (clinicaltrials.gov)
    P1, N=36, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    1m
    Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder. (clinicaltrials.gov)
    P1, N=95, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.
    New P1 trial
    |
    olanzapine
    1m
    An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia (clinicaltrials.gov)
    P1, N=116, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.
    New P1 trial
    |
    olanzapine
    1m
    Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)
    P4, N=80, Recruiting, Icahn School of Medicine at Mount Sinai | Initiation date: Feb 2024 --> May 2024
    Trial initiation date
    |
    olanzapine
    2ms
    Serum S100B Protein and White Matter Changes in Schizophrenia before and after Medication. (PubMed, Brain Res Bull)
    Our findings demonstrated abnormalities in S100B and WM microstructure in patients with schizophrenia. These abnormalities may be partly reversed by quetiapine treatment.
    Journal
    |
    S100B (S100 Calcium Binding Protein B)
    2ms
    PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Intra-Cellular Therapies, Inc.
    New P1 trial
    2ms
    Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients (clinicaltrials.gov)
    P3, N=62, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting | N=170 --> 62
    Enrollment closed • Enrollment change
    |
    carboplatin • paclitaxel • fosaprepitant • olanzapine • ondansetron
    2ms
    Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (clinicaltrials.gov)
    P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Feb 2024 --> Jun 2024
    Trial completion date • Metastases
    |
    olanzapine
    2ms
    Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov)
    P2/3, N=40, Completed, Charite University, Berlin, Germany | Unknown status --> Completed
    Trial completion
    |
    olanzapine • riluzole
    3ms
    SOLARIS: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (clinicaltrials.gov)
    P3, N=640, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    olanzapine
    3ms
    Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 (clinicaltrials.gov)
    P3, N=524, Completed, Alkermes, Inc. | Active, not recruiting --> Completed
    Trial completion
    3ms
    Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Teva Branded Pharmaceutical Products R&D, Inc.
    New P1 trial
    |
    olanzapine
    3ms
    Drug Interaction Study (clinicaltrials.gov)
    P1, N=40, Recruiting, Emalex Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • rifampicin
    3ms
    The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions. (PubMed, J Exp Clin Cancer Res)
    DRD1 contributes to GBM invasion and progression by regulating c-Myc entry into the nucleus that affects the transcription of the UHRF1 gene. SKF83566 inhibits the transmembrane protein DRD1, and as such represents a candidate small therapeutic molecule for GBMs.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1) • DRD5 (Dopamine Receptor D5)
    |
    MYC expression
    3ms
    A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, Central Institute of Mental Health, Mannheim | Trial completion date: Aug 2022 --> Jun 2025 | Trial primary completion date: May 2022 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    olanzapine
    3ms
    LBL: Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (clinicaltrials.gov)
    P1, N=20, Recruiting, University Hospital, Basel, Switzerland | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    3ms
    Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan (clinicaltrials.gov)
    P3, N=52, Completed, Rush University Medical Center | N=429 --> 52
    Enrollment change
    |
    melphalan • aprepitant oral • olanzapine
    4ms
    Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial (clinicaltrials.gov)
    P3, N=87, Not yet recruiting, M.D. Anderson Cancer Center
    New P3 trial
    |
    olanzapine
    4ms
    Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)
    P4, N=80, Recruiting, Icahn School of Medicine at Mount Sinai | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    4ms
    Drug Interaction Study (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Emalex Biosciences Inc.
    New P1 trial
    |
    itraconazole • rifampicin
    4ms
    Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects (clinicaltrials.gov)
    P3, N=236, Enrolling by invitation, Alkermes, Inc.
    Trial completion date • Trial primary completion date
    4ms
    LAMP: Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum (clinicaltrials.gov)
    P=N/A, N=125, Recruiting, University of Liverpool
    Trial completion date
    |
    fluphenazine
    5ms
    Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (clinicaltrials.gov)
    P3, N=220, Recruiting, Alkermes, Inc.
    Trial completion date • Trial primary completion date
    5ms
    Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (clinicaltrials.gov)
    P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Aug 2023 --> Feb 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    olanzapine
    5ms
    Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)
    P4, N=80, Not yet recruiting, Icahn School of Medicine at Mount Sinai
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    olanzapine
    5ms
    Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder (clinicaltrials.gov)
    P1, N=7, Completed, Alkermes, Inc. | Recruiting --> Completed | N=12 --> 7 | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jun 2024 --> Aug 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    5ms
    Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). (PubMed, Br J Cancer)
    DEX-sparing is an alternative option for patients receiving cisplatin; however, this revised administration schedule should be applied on an individual basis after a comprehensive evaluation.
    P3 data • Journal
    |
    B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
    |
    cisplatin • olanzapine
    6ms
    Psychopharmacological Treatment of Emotional Distress (clinicaltrials.gov)
    P4, N=80, Not yet recruiting, Icahn School of Medicine at Mount Sinai
    New P4 trial
    |
    olanzapine
    6ms
    National Pregnancy Registry for Psychiatric Medications (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Massachusetts General Hospital | N=2500 --> 5000
    Enrollment change
    6ms
    The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Peking University
    New trial
    |
    olanzapine
    6ms
    Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (clinicaltrials.gov)
    P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Feb 2024 --> Aug 2023 | Trial primary completion date: Feb 2024 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    olanzapine